Glaxo Handing Over Record $3B To Settle FCA Claims

By Jeff Overley (July 2, 2012, 2:03 PM EDT) -- GlaxoSmithKline PLC will plead guilty and pay a record-setting $3 billion penalty to resolve whistleblower charges that it promoted drugs for unapproved uses, omitted safety data about its medicines and violated the False Claims Act by doling out kickbacks, prosecutors said Monday.

Under the settlement, U.K.-based GSK will enter guilty pleas on three counts involving some of its most prominent treatments. Those charges, which carry fines totaling $1 billion, include failing to report data to the U.S. Food and Drug Administration about diabetes drug Avandia and misbranding of antidepressants Paxil and Wellbutrin.

In addition, the company will hand over $2 billion...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!